CSL Ltd CMXHF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CMXHF is a good fit for your portfolio.
News
-
CSL Says 1st Half Profit Rises, Boosts Dividend — Update
-
CSL Says 1st Half Profit Rises, Boosts Dividend
-
CSL Says Cardiovascular Drug CSL112 Didn't Meet 'Efficacy Endpoint' After Study
-
CSL's Hemgenix Authorized by Health Canada as Gene Therapy for Hemophilia B
-
CSL Annual Profit Rises 8% at Constant FX
-
CSL Forecasts 13-18% Growth in Fiscal Year 2024 Net Profit
-
Travere Therapeutics Shares Touch 52-Week Low on FSGS Study Data
Trading Information
- Previous Close Price
- $176.00
- Day Range
- $178.45–180.73
- 52-Week Range
- $144.81–207.67
- Bid/Ask
- $177.50 / $184.00
- Market Cap
- $86.24 Bil
- Volume/Avg
- 173 / 189
Key Statistics
- Price/Earnings (Normalized)
- 27.36
- Price/Sales
- 6.09
- Dividend Yield (Trailing)
- 1.38%
- Dividend Yield (Forward)
- 1.38%
- Total Yield
- 1.42%
Company Profile
CSL is one of the largest global biotech companies and has two main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders and neurological indications. Seqirus is now the world’s second largest influenza vaccination business and was acquired in fiscal 2015. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Large Growth
- Total Number of Employees
- 30,000
- Website
- https://www.csl.com
Competitors
Valuation
|
Metric
|
CMXHF
|
SNY
|
GRF.P
|
|---|---|---|---|
Price/Earnings (Normalized) | 27.36 | 10.04 | 24.77 |
Price/Book Value | 4.95 | 1.56 | 0.69 |
Price/Sales | 6.09 | 2.38 | 0.61 |
Price/Cash Flow | 31.75 | 11.66 | 6.92 |
Price/Earnings
CMXHF
SNY
GRF.P
Financial Strength
|
Metric
|
CMXHF
|
SNY
|
GRF.P
|
|---|---|---|---|
Quick Ratio | 0.95 | 0.83 | 0.72 |
Current Ratio | 2.15 | 1.27 | 2.48 |
Interest Coverage | 7.21 | 11.03 | 1.28 |
Quick Ratio
CMXHF
SNY
GRF.P
Profitability
|
Metric
|
CMXHF
|
SNY
|
GRF.P
|
|---|---|---|---|
Return on Assets (Normalized) | 8.11% | 8.05% | 1.30% |
Return on Equity (Normalized) | 18.17% | 14.38% | 4.69% |
Return on Invested Capital (Normalized) | 10.94% | 10.85% | 3.45% |
Return on Assets
CMXHF
SNY
GRF.P
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Lpthmjlj | Nyskv | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Tpkykxnr | Yvmkzl | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Hjbhfjnp | Lnzlz | $99.5 Bil | |
MRNA
| Moderna Inc | Rnpktgcgx | Gcb | $38.8 Bil | |
ARGX
| argenx SE ADR | Jblbvgrmf | Vbkw | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Mnscprn | Nzfzx | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Vbqfvsb | Tqmrwz | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Chfkbymfl | Gltrck | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Cjpmnlnyxg | Kzdmh | $12.5 Bil | |
INCY
| Incyte Corp | Wxhlhyrz | Mncbqg | $11.6 Bil |